# MEVPRO-2 (NCT06629779)

> A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06629779
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Pfizer
- Conditions: Metastatic Castration-Resistant Prostate Cancer
- Interventions: PF-06821497; Placebo; Enzalutamide
- Enrollment: 900
- Primary outcome: Radiographic Progression Free Survival (rPFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 9
- YouTube: 7
- Podcasts: 3
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=mevpro-2-nct06629779

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06629779", "email": "<work email>"}; the inbox owner confirms by the emailed link.